Compare JFIN & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JFIN | PMN |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.7M | 84.1M |
| IPO Year | 2018 | 2022 |
| Metric | JFIN | PMN |
|---|---|---|
| Price | $1.44 | $3.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $42.40 |
| AVG Volume (30 Days) | ★ 591.0K | 390.1K |
| Earning Date | 11-27-2026 | 11-12-2026 |
| Dividend Yield | ★ 58.39% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.13 | $0.29 |
| 52 Week High | $8.83 | $27.40 |
| Indicator | JFIN | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 42.39 | 30.28 |
| Support Level | $1.21 | $2.78 |
| Resistance Level | $1.43 | $15.05 |
| Average True Range (ATR) | 0.16 | 1.07 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 14.85 | 6.01 |
Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.